| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/MDS.26120 |
| P698 | PubMed publication ID | 25488030 |
| P50 | author | Andrew John Lees | Q4757729 |
| Eduardo Tolosa | Q64754997 | ||
| Charles Warren Olanow | Q66933446 | ||
| P2860 | cites work | Protein Intake and Treatment of Parkinson's Disease with Levodopa | Q23913771 |
| Similarities between Neurologic Effects of L-Dopa and of Apomorphine | Q28247371 | ||
| Parkinsonism: onset, progression, and mortality | Q28259134 | ||
| Treatment of Parkinson's disease with aporphines. Possible role of growth hormone | Q28336989 | ||
| Cholinergic effects of molecular segments of apomorphine and dopaminergic effects of N,N-dialkylated dopamines | Q28341629 | ||
| Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases | Q29614910 | ||
| Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease? | Q34044620 | ||
| Treatment of Parkinsonism With Levodopa | Q34240368 | ||
| 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists | Q34242473 | ||
| Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system | Q34248307 | ||
| Levodopa and the progression of Parkinson's disease | Q34553278 | ||
| Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems | Q34732654 | ||
| L-3,4-dihydroxyphenylalanine-induced hypersensitivity simulating features of denervation | Q35028210 | ||
| A clinical trial of Rauwolfia serpentina in essential hypertension | Q39673325 | ||
| Injected apomorphine and orally administered levodopa in Parkinsonism | Q43611375 | ||
| Dopamine miracle: from brain homogenate to dopamine replacement | Q44060153 | ||
| Tic reduction with pergolide in a randomized controlled trial in children | Q44324832 | ||
| Modification of Parkinsonism--chronic treatment with L-dopa | Q45300970 | ||
| Apomorphine in Huntington's chorea: clinical observations and theoretical considerations | Q45303166 | ||
| "Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease | Q45309188 | ||
| An adenylate cyclase of brain reflects propensity for breast cancer in mice | Q48265358 | ||
| Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum | Q48301354 | ||
| Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system | Q49135571 | ||
| Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial | Q50454449 | ||
| Levodopa in Parkinsonism: Potentiation of Central Effects with a Peripheral Inhibitor | Q51107835 | ||
| Evidence for a new type of dopamine receptor stimulating agent. | Q51116671 | ||
| Increase of Cerebral Catecholamines caused by 3,4-Dihydroxyphenylalanine after Inhibition of Peripheral Decarboxylase | Q51208477 | ||
| TREMORINE-INDUCED TREMOR VERSUS EXTRAPYRAMIDAL DISEASE. | Q51277162 | ||
| Excretion of dopamine in diseases of basal ganglia. | Q51302153 | ||
| Distribution of catechol compounds in human brain | Q51315805 | ||
| Occurrence and distribution of dopamine in brain and other tissues. | Q51316949 | ||
| On the presence of 3-hydroxytyramine in brain. | Q51322287 | ||
| Catechol compounds in rat tissues and in brains of different animals. | Q51325237 | ||
| Evidence that serotonin has a role in brain function. | Q51334538 | ||
| Use of Rauwolfia serpentina Benth. in neuropsychiatric conditions. | Q52174660 | ||
| A Personal Tribute to Dr. George C. Cotzias, Clinician and Scientist | Q52411806 | ||
| Bromocriptine in Parkinsonism. | Q54333277 | ||
| Manganese in Melanin | Q59074722 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 19-36 | |
| P577 | publication date | 2014-12-08 | |
| P1433 | published in | Movement Disorders | Q1486418 |
| P1476 | title | Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr | |
| P478 | volume | 30 |
| Q57143848 | Animal models of neurodegenerative diseases |
| Q48357239 | Can levodopa-induced dyskinesias go beyond the motor circuit? |
| Q38947463 | Clinical pharmacology review of opicapone for the treatment of Parkinson's disease |
| Q28078561 | Diversity matters - heterogeneity of dopaminergic neurons in the ventral mesencephalon and its relation to Parkinson's Disease |
| Q50502365 | Efficacy and Safety of Adjuvant Treatment with Entacapone in Advanced Parkinson's Disease with Motor Fluctuation: A Systematic Meta-Analysis. |
| Q42655862 | Factors associated with motor complications in Parkinson's disease. |
| Q92445892 | L-DOPA in Parkinson's Disease: Looking at the "False" Neurotransmitters and Their Meaning |
| Q48056860 | Levodopa: 50 years of a revolutionary drug for Parkinson disease |
| Q28066691 | Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases |
| Q38943872 | Opicapone for the treatment of Parkinson's disease |
| Q99630702 | Parkinson's Disease: Unanticipated Sequela of an Attempted Suicide |
| Q36565693 | Rapid Recovery of Vesicular Dopamine Levels in Methamphetamine Users in Early Abstinence |
| Q89792742 | Strategies for the Treatment of Parkinson's Disease: Beyond Dopamine |
| Q47876389 | Striatal But Not Extrastriatal Dopamine Receptors Are Critical to Dopaminergic Motor Stimulation |
| Q37693375 | The Synucleinopathies: Twenty Years On. |
Search more.